| scholarly article | Q13442814 |
| P2093 | author name string | Akira Kagayama | |
| Yoichi Naritomi | |||
| Yoshimasa Imamura | |||
| Takeshi Ishikawa | |||
| Seitaro Mutoh | |||
| Yoshitaka Ohkubo | |||
| Fusako Nishigaki | |||
| Yoshitaka Hirayama | |||
| Susumu Miyata | |||
| Kyoko Minoura | |||
| Masahiro Neya | |||
| Junko Imanishi | |||
| Tsuyoshi Mizutani | |||
| Hidetsugu Murai | |||
| P2860 | cites work | Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis | Q24610450 |
| A factor derived from polymorphonuclear leukocytes enhances interleukin-1-induced synovial cell collagenase and prostaglandin E2 production in rats | Q28582708 | ||
| Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease | Q28618841 | ||
| Tumor targeting with a selective gelatinase inhibitor | Q30747366 | ||
| Animal models of rheumatoid arthritis | Q33727732 | ||
| Matrix metalloproteinases in tumour invasion and metastasis | Q33765792 | ||
| The impact of pharmaco-economic considerations on the utilization of novel anti-rheumatic therapies | Q33824003 | ||
| Proteinases in bone resorption: obvious and less obvious roles. | Q33838178 | ||
| Matrix metalloproteinases and venous leg ulceration | Q33868197 | ||
| Expression and regulation of aggrecanase in arthritis: the role of TGF-beta | Q34110312 | ||
| VDIPEN, a metalloproteinase-generated neoepitope, is induced and immunolocalized in articular cartilage during inflammatory arthritis | Q34217504 | ||
| Selective matrix metalloproteinase (MMP) inhibition in rheumatoid arthritis--targetting gelatinase A activation | Q34273821 | ||
| How do the biologics fit into the current DMARD armamentarium? | Q34284422 | ||
| Composition and structure of articular cartilage: a template for tissue repair | Q34403189 | ||
| Matrix metalloproteinases as therapeutic targets in arthritic diseases: bull's-eye or missing the mark? | Q34510718 | ||
| Matrix metalloproteinase inhibitors in rheumatic diseases | Q34560579 | ||
| Immunohistochemical detection and immunochemical analysis of type II collagen degradation in human normal, rheumatoid, and osteoarthritic articular cartilages and in explants of bovine articular cartilage cultured with interleukin 1 | Q34566923 | ||
| Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo | Q35026212 | ||
| Extracellular matrix remodelling: the role of matrix metalloproteinases | Q35170432 | ||
| Matrix metalloproteinases A review of their structure and role in acute coronary syndrome | Q35557333 | ||
| Infections and anti–tumor necrosis factor α therapy | Q35581950 | ||
| MT1-MMP: a tethered collagenase | Q35770291 | ||
| Role of matrix metalloproteinases in failure to re-epithelialize after corneal injury | Q35782239 | ||
| An immunoelectron microscope study of the organization of proteoglycan monomer, link protein, and collagen in the matrix of articular cartilage | Q36206142 | ||
| Autoimmunity to type II collagen an experimental model of arthritis | Q36335891 | ||
| IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion | Q37202023 | ||
| Aggrecan is degraded by matrix metalloproteinases in human arthritis. Evidence that matrix metalloproteinase and aggrecanase activities can be independent | Q37361470 | ||
| Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints | Q37369629 | ||
| Collagen arthritis as a relevant model for rheumatoid arthritis | Q40338367 | ||
| Using inhibitors of metalloproteinases to treat arthritis. Easier said than done? | Q40684838 | ||
| Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules | Q41133261 | ||
| Suppression of adjuvant arthritis of rats by a novel matrix metalloproteinase-inhibitor | Q43264390 | ||
| Comparison of collagenase-cleaved articular cartilage collagen in mice in the naturally occurring STR/ort model of osteoarthritis and in collagen-induced arthritis | Q43898917 | ||
| Collagen-induced arthritis in rats. Evaluation of early immunologic events | Q44196191 | ||
| A microplate assay specific for the enzyme aggrecanase | Q44373998 | ||
| Aggrecan protects cartilage collagen from proteolytic cleavage | Q47724408 | ||
| Collagen-induced arthritis in rhesus monkeys: evaluation of markers for inflammation and joint degradation. | Q54140227 | ||
| Immunisation against heterologous type II collagen induces arthritis in mice | Q59053172 | ||
| Joint destruction in arthritis: metalloproteinases in the spotlight | Q68028254 | ||
| Tissue distribution and clearance of soluble murine TNF receptors in mice | Q72639124 | ||
| Susceptibility of stromelysin 1-deficient mice to collagen-induced arthritis and cartilage destruction | Q74060223 | ||
| Reduced angiogenesis and tumor progression in gelatinase A-deficient mice | Q74309789 | ||
| Aggrecanase and metalloproteinase-specific aggrecan neo-epitopes are induced in the articular cartilage of mice with collagen II-induced arthritis | Q74425441 | ||
| Prevention of cartilage breakdown by matrix metalloproteinase inhibition--a realistic therapeutic target? | Q74628449 | ||
| Ro 32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis | Q77341396 | ||
| Complex role of matrix metalloproteinases in angiogenesis | Q77474882 | ||
| Kinetics of aggrecanase- and metalloproteinase-induced neoepitopes in various stages of cartilage destruction in murine arthritis | Q77872978 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 133-143 | |
| P577 | publication date | 2005-01-01 | |
| P1433 | published in | British Journal of Pharmacology | Q919631 |
| P1476 | title | Prevention of progressive joint destruction in collagen-induced arthritis in rats by a novel matrix metalloproteinase inhibitor, FR255031. | |
| P478 | volume | 144 |
| Q35907768 | A2A and A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release |
| Q35228585 | Anti-arthritic activity of Fu-Fang-Lu-Jiao-Shuang on collagen-induced arthritis in Balb/c mice and its underlying mechanisms |
| Q42969654 | Anti-inflammatory activities of light emitting diode irradiation on collagen-induced arthritis in mice (a secondary publication). |
| Q89964334 | Destroy to Rebuild: The Connection Between Bone Tissue Remodeling and Matrix Metalloproteinases |
| Q37701473 | Early detection of rheumatoid arthritis in rats and humans with 99mTc-3PRGD2 scintigraphy: imaging synovial neoangiogenesis |
| Q35161309 | Effect of methotrexate on collagen-induced arthritis assessed by micro-computed tomography and histopathological examination in female rats |
| Q92908043 | Effect of methotrexate on collagen-induced arthritis in male Wistar rats |
| Q33694487 | Extracellular matrix molecules: potential targets in pharmacotherapy. |
| Q64910209 | Impact of gentamicin-supplemented polyvinylidenfluoride mesh materials on MMP-2 expression and tissue integration in a transgenic mice model. |
| Q45713557 | Influence of gentamicin-coded PVDF suture material on the healing of intestinal anastomosis in a rat model |
| Q43161105 | Inhibition of interleukin-1beta-induced matrix metalloproteinases 1 and 13 production in human osteoarthritic chondrocytes by prostaglandin D2. |
| Q41962820 | Macrophage migration inhibitory factor: a mediator of matrix metalloproteinase-2 production in rheumatoid arthritis. |
| Q26741827 | Matrix Metalloproteinases in Non-Neoplastic Disorders |
| Q37030862 | Metalloproteases as potential therapeutic targets in arthritis treatment |
| Q35790241 | Micro-computed tomography evaluation and pathological analyses of female rats with collagen-induced arthritis |
| Q53177164 | Protective effects of ginsenoside Rg3 on human osteoarthritic chondrocytes. |
| Q62738057 | Repetitive Aerosol Exposure Promotes Cavitary Tuberculosis and Enables Screening for Targeted Inhibitors of Extensive Lung Destruction |
| Q34801330 | Role of matrix metalloproteinases and therapeutic benefits of their inhibition in spinal cord injury |
| Q33269680 | Type II collagen without adjuvant induces eosinophilic arthritis |
Search more.